Pharmarise Holdings (2796) · RiskAdvanced
Transition and Physical Climate Risks and Responses
First written in FY2024. 2 of 3 entries say "Advanced", first in FY2025. Latest entry: FY2026.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
TCFD-Based Climate Change Scenario Analysis and DisclosureA theme 563 companies write about · 117 as a headwind · 331 as a tailwind
90 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 195 companies compared. The sentences above are computed from all 195.Comparing 200 of the theme's 579 threads.Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「The Group examined its risks and opportunities using 2 representative scenarios, 1) a transition risk scenario (a scenario of 1.5°C or below) and 2) a physical risk scenario (a 4.0°C scenario).」
For climate-related risks, the Company specified the timing of their emergence, financial impacts and response measures, including improving power and transportation efficiency, BCP and pharmaceutical stockpiling. - FY2025AdvancedAnnual report
「Using 2 representative scenarios, 1) a transition risk scenario (a scenario of 1.5°C or below) and 2) a physical risk scenario (a 4.0°C scenario), the Group examined its risks and opportunities.」
For climate-related risks, the Company specified the timing of their emergence, financial impacts and response measures, including improving power and transportation efficiency, BCP and pharmaceutical stockpiling, under the 1.5°C and 4.0°C scenarios. - FY2024First statedAnnual report
「Using 2 representative scenarios, 1) a transition risk scenario (a scenario of 1.5°C or below) and 2) a physical risk scenario (a 4.0°C scenario), the Group examined its risks and opportunities.」
Climate-related risks, including carbon pricing, transportation costs, flooding, rising temperatures, major disasters and instability in the pharmaceutical supply, together with response measures, were systematically disclosed for the first time under the 1.5°C and 4.0°C scenarios.